277 related articles for article (PubMed ID: 25331116)
21. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.
Gómez-Benito M; Conchillo A; García MA; Vázquez I; Maicas M; Vicente C; Cristobal I; Marcotegui N; García-Ortí L; Bandrés E; Calasanz MJ; Alonso MM; Odero MD
Br J Cancer; 2010 Oct; 103(8):1292-6. PubMed ID: 20842122
[TBL] [Abstract][Full Text] [Related]
22. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Shiba N; Ohki K; Hayashi Y; Yamashita Y; Shimada A; Tanaka S; Adachi S
Haematologica; 2014 Nov; 99(11):e225-7. PubMed ID: 25015941
[No Abstract] [Full Text] [Related]
23. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
[TBL] [Abstract][Full Text] [Related]
24. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
[TBL] [Abstract][Full Text] [Related]
25. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
[TBL] [Abstract][Full Text] [Related]
26. EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
[TBL] [Abstract][Full Text] [Related]
27. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
28. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
[TBL] [Abstract][Full Text] [Related]
29. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M
Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993
[TBL] [Abstract][Full Text] [Related]
30. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
31. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
[TBL] [Abstract][Full Text] [Related]
32. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target.
Yamamoto H; Lu J; Oba S; Kawamata T; Yoshimi A; Kurosaki N; Yokoyama K; Matsushita H; Kurokawa M; Tojo A; Ando K; Morishita K; Katagiri K; Kotani A
Sci Rep; 2016 Jan; 6():19204. PubMed ID: 26754824
[TBL] [Abstract][Full Text] [Related]
33. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
Watanabe-Okochi N; Yoshimi A; Sato T; Ikeda T; Kumano K; Taoka K; Satoh Y; Shinohara A; Tsuruta T; Masuda A; Yokota H; Yatomi Y; Takahashi K; Kitaura J; Kitamura T; Kurokawa M
Blood; 2013 May; 121(20):4142-55. PubMed ID: 23547050
[TBL] [Abstract][Full Text] [Related]
34. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
35. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
[TBL] [Abstract][Full Text] [Related]
36. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.
Morishita K; Parganas E; William CL; Whittaker MH; Drabkin H; Oval J; Taetle R; Valentine MB; Ihle JN
Proc Natl Acad Sci U S A; 1992 May; 89(9):3937-41. PubMed ID: 1570317
[TBL] [Abstract][Full Text] [Related]
37. Dysregulated EVI1 expression in myeloid malignancies.
Pardanani A
Leuk Lymphoma; 2006 Dec; 47(12):2443-4. PubMed ID: 17169788
[No Abstract] [Full Text] [Related]
38. [EVI1 expression, clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia].
He XF; Wang QR; Cen JN; Qiu HY; Sun AN; Chen SN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):936-941. PubMed ID: 27995876
[TBL] [Abstract][Full Text] [Related]
39. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
40. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
Vázquez I; Maicas M; Marcotegui N; Conchillo A; Guruceaga E; Roman-Gomez J; Calasanz MJ; Agirre X; Prosper F; Odero MD
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):E167-8; author reply E169-70. PubMed ID: 20930122
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
